A carregar...
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
BACKGROUND: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multi...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4021072/ https://ncbi.nlm.nih.gov/pubmed/24423155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-14-12 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|